European principles of inhibitor management in patients with haemophilia

[1]  S. Cessie,et al.  Intensity of factor VIII treatment and the development of inhibitors in non‐severe hemophilia A patients: results of the INSIGHT case–control study , 2017, Journal of thrombosis and haemostasis : JTH.

[2]  P. Mannucci,et al.  Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A , 2016, Journal of thrombosis and haemostasis : JTH.

[3]  E. Berntorp.  Future of haemophilia outcome assessment: registries are key to optimized treatment , 2016, Journal of internal medicine.

[4]  V. Ramanan,et al.  A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. , 2016, The New England journal of medicine.

[5]  P. Elfvinge,et al.  A European curriculum for nurses working in haemophilia , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  A. Iorio,et al.  Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. , 2015, The Cochrane database of systematic reviews.

[7]  C. Miller.  Improving the performance of factor VIII inhibitor tests in hemophilia A. , 2015, Thrombosis research.

[8]  P. Giangrande,et al.  Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors. , 2015, Blood reviews.

[9]  V. Jiménez‐Yuste,et al.  Inhibitors in nonsevere haemophilia A: outcome and eradication strategies , 2015, Thrombosis and Haemostasis.

[10]  R. Liesner,et al.  The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full‐length to B‐domain‐deleted factor VIII: a prospective cohort comparison , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  P. Giangrande,et al.  The European standards of Haemophilia Centres. , 2014, Blood transfusion = Trasfusione del sangue.

[12]  R. Ljung,et al.  Increased burden on caregivers of having a child with haemophilia complicated by inhibitors , 2014, Pediatric blood & cancer.

[13]  J. Anderson,et al.  Guidance on the dental management of patients with haemophilia and congenital bleeding disorders , 2013, BDJ.

[14]  J. Astermark,et al.  GENERAL INTRODUCTION AND OUTLINE OF THE THESIS , 2012 .

[15]  K. Khair,et al.  Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  C. Négrier,et al.  Consensus recommendations for the use of FEIBA® in haemophilia A patients with inhibitors undergoing elective orthopaedic and non‐orthopaedic surgery , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  P. Elfvinge,et al.  The role of the European haemophilia nurse , 2013 .

[18]  R. Liesner,et al.  Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition) , 2013, British journal of haematology.

[19]  J. Stockman.  Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom , 2013 .

[20]  G. Benson,et al.  Management of muscle haematomas in patients with severe haemophilia in an evidence‐poor world , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  P. Mannucci,et al.  Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A , 2012, Journal of thrombosis and haemostasis : JTH.

[22]  J. Astermark,et al.  Recommendations for assessment, monitoring and follow‐up of patients with haemophilia , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  C. Hay,et al.  The principal results of the International Immune Tolerance Study: a randomized dose comparison. , 2012, Blood.

[24]  R. Liesner,et al.  Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. , 2011, Blood.

[25]  V. Jiménez‐Yuste,et al.  Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  J. Astermark,et al.  European principles of haemophilia care , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  J. Astermark,et al.  A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. , 2007, Blood.

[28]  F. Cassis.  PSYCHOSOCIAL CARE FOR PEOPLE WITH HEMOPHILIA , 2007 .

[29]  J. Astermark.  Overview of inhibitors. , 2006, Seminars in hematology.

[30]  J. Oldenburg,et al.  Environmental and genetic factors influencing inhibitor development. , 2004, Seminars in hematology.

[31]  A. Girolami,et al.  Psychological aspects and coping in haemophilic patients: a case–control study , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[32]  B. Evatt,et al.  Occurrence of hemophilia in the United States , 1998 .

[33]  B. Evatt,et al.  Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. , 1998, American journal of hematology.

[34]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.